The Efficacy of Platelet-rich Plasma Injection in the Treatment of Knee Osteoarthritis: A Systematic Review by Howell, Yvonne
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
Summer 8-10-2013
The Efficacy of Platelet-rich Plasma Injection in the
Treatment of Knee Osteoarthritis: A Systematic
Review
Yvonne Howell
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Howell, Yvonne, "The Efficacy of Platelet-rich Plasma Injection in the Treatment of Knee Osteoarthritis: A Systematic Review"
(2013). School of Physician Assistant Studies. Paper 449.
The Efficacy of Platelet-rich Plasma Injection in the Treatment of Knee
Osteoarthritis: A Systematic Review
Abstract
Background: Increased physical activities and prolonged life expectancies, coupled with biomechanical,
metabolic, and biological changes of articular cartilage, have led to a significant rise in osteoarthritis.
Unfortunately, cartilage lesions are difficult to treat because of their inherit limit of adequate blood and nerve
supplies, which decreases healing potential. There are numerous, non-invasive treatment approaches with
emphasis on pain management, improvement in function, and hindering the disease progress. But most of
them are of short-term success with significant side effects, and do not address the biological pathology. New
experimental studies have targeted the biomechanical process of OA with the focus on promoting cartilage
repair or replacement. Can platelet rich-plasma (PRP) be an effective alternative option in the treatment of
knee OA?
Method: An extensive search of the literature using Medline, CINAHL, Web of Science, and Google Scholar
was conducted with the help of the following keywords: platelet-rich plasma, cartilage, injections, and
osteoarthritis. For the purpose of performing a systematic review, articles that identified the effects of PRP
injections on OA were selected and assessed via the GRADE system.
Results: Three articles were selected which directly addressed the question and met the inclusion and
exclusion criteria. One prospective cohort study of 150 participants showed statistically significant
improvements in pain, function and patient satisfaction with PRP treatment after 2 and 6 month follow up
when compared to hyaluronic acid (HA) injections. Another cohort study of 120 individuals displayed safe
and effective outcomes in pain reduction and recovery of function over HA treatments. However, major
changes were only noticeable during the first 3 months. A retrospective study observed success rate of 33.3%
by week 5 in the PRP group versus 10% in the control group.
Conclusion: All of the studies suggest that PRP injections are a good alternative in the treatment of OA. This
procedure showed a higher degree of efficacy in pain reduction, improved function, and patient satisfaction
compared to current options. No complications were identified. However, more research is needed, with
emphasis on blinded randomized control trials, to further confirm current findings, determine precise
mechanism of action, its disease-modifying properties, and possible long-term relief.
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Abstract   
 
Background:  Increased physical activities and prolonged life expectancies, coupled 
with biomechanical, metabolic, and biological changes of articular cartilage, have led to a 
significant rise in osteoarthritis. Unfortunately, cartilage lesions are difficult to treat 
because of their inherit limit of adequate blood and nerve supplies, which decreases 
healing potential. There are numerous, non-invasive treatment approaches with emphasis 
on pain management, improvement in function, and hindering the disease progress. But 
most of them are of short-term success with significant side effects, and do not address 
the biological pathology. New experimental studies have targeted the biomechanical 
process of OA with the focus on promoting cartilage repair or replacement. Can platelet 
rich-plasma (PRP) be an effective alternative option in the treatment of knee OA?   
Method:  An extensive search of the literature using Medline, CINAHL, Web of Science, 
and Google Scholar was conducted with the help of the following keywords: platelet-rich 
plasma, cartilage, injections, and osteoarthritis. For the purpose of performing a 
systematic review, articles that identified the effects of PRP injections on OA were 
selected and assessed via the GRADE system. 
Results:  Three articles were selected which directly addressed the question and met the 
inclusion and exclusion criteria. One prospective cohort study of 150 participants showed 
statistically significant improvements in pain, function and patient satisfaction with PRP 
treatment after 2 and 6 month follow up when compared to hyaluronic acid (HA) 
injections. Another cohort study of 120 individuals displayed safe and effective outcomes 
in pain reduction and recovery of function over HA treatments. However, major changes 
were only noticeable during the first 3 months. A retrospective study observed success 
rate of 33.3% by week 5 in the PRP group versus 10% in the control group.   
Conclusion:  All of the studies suggest that PRP injections are a good alternative in the 
treatment of OA. This procedure showed a higher degree of efficacy in pain reduction, 
improved function, and patient satisfaction compared to current options. No 
complications were identified. However, more research is needed, with emphasis on 
blinded randomized control trials, to further confirm current findings, determine precise 
mechanism of action, its disease-modifying properties, and possible long-term relief.  
Keywords:  platelet-rich plasma, injections, cartilage, and osteoarthritis 
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The Efficacy of Platelet-rich Plasma Injection in the Treatment of Knee 
Osteoarthritis: A Systematic Review 
 
BACKGROUND 
Osteoarthritis (OA) is the most common form of arthritis afflicting mankind, 
especially the older population. This disease spares no race, gender, or geographical 
area.1,2 One of the most frequently affected joints is the knee. Osteoarthritis’s 
characteristic symptoms are pain, swelling, and stiffness with a decline in physical 
function such as walking, climbing stairs, and getting in and out of a chair. In many cases 
OA can be debilitating, leading to a diminished quality of life.  Lawrence et al1 states that 
approximately 27 million Americans over the age of 25 currently suffer from OA. This 
number is predicted to increase by 2030 to a staggering 67million.3 Increased physical 
activities as well as prolonged life expectancies, coupled with biomechanical, metabolic, 
and biological changes of articular cartilage, have led to a significant rise in OA. 
Unfortunately, articular cartilage lesions are difficult to treat because of their inherent 
limit of adequate blood and nerve supplies, and with that decreased healing potential.4,5 
Homeostasis of extracellular matrix is impaired, inflammatory process is unavailable, and 
chondrocyte migration is diminished resulting in cartilage destruction, chondral bone 
alterations, and synovitis.6,7   
At present, there are numerous, non-invasive treatment approaches with emphasis 
on pain management, improvement in function and the potential to modify the disease 
process and progress of cartilage degeneration.5,8 Such treatment options include 
analgesic, steroid and non-steroid anti-inflammatory drugs, glucosamine/chondroitin 
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supplementation, physical therapy, and hyaluronic acid (HA) injections. However, most 
of them have either been of short-term success, not addressing the biological pathology or 
have shown only minor benefits and significant side effects.9 New experimental studies 
have begun to target the biomechanical process of OA with the focus on promoting 
cartilage repair or replacement. Particular attention has been directed toward autologous 
platelet-rich plasma (PRP); a high concentration of platelets suspended in a small volume 
of plasma after being placed in a centrifuge.6 Platelets play an essential part in tissue 
homeostasis. They contain a vast number of growth factors, cytokines, and bioactive 
proteins which help regulate tissue healing and restoration. Past studies of PRP 
applications have shown an increase in “cell proliferation, migration, differentiation, 
inflammation mediation, and matrix synthesis.” 6,7  
The aim of this systematic review is to evaluate the efficacy of platelet-rich 
plasma in the treatment of knee osteoarthritis. 
METHODS 
An extensive search of the literature was conducted using Medline, CINAHL, 
Web of Science, and Google Scholar; accessed through the Pacific University Library 
system. The keyword terms “platelet-rich plasma, injections, cartilage, and osteoarthritis” 
were searched individually and in combination. The results were limited to the English 
language, human subject trials, and publications since 2007. Articles that contained study 
designs other than randomized controlled trials (RCT), cohort studies, and case control 
studies were excluded. Duplicates, re-publications, descriptive reviews, and letters to the 
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editor were dismissed. The selected articles were analyzed for quality using the Grading 
of Recommendations, Assessment, Development and Evaluation (GRADE) framework.10 
RESULTS 
The initial literature search yielded 23 articles that were screened for relevance to 
the clinical question. Five articles remained, of which 3 studies met the inclusion and 
exclusion criteria and were included in the systematic review. All three studies were of 
either prospective or retrospective cohort methodology and none were randomized 
control trials. Table 1 provides a summary of the studies that were included in the 
systematic review.  
Kon et al Trial  
 Patient selection--The purpose of this prospective cohort study11 was to explore 
the effectiveness of PRP injections as a possible alternative therapy option in the 
treatment of knee articular cartilage degeneration. Outcomes were analyzed and 
compared to hyaluronic acid (HA) intra-articular injection therapy. Eligibility criteria 
included history of chronic knee pain or swelling (>4 months), x-ray and MRI findings of 
articular cartilage degeneration, and knee surgeries no less than one year prior to the start 
of this trial. Immunosuppressed patients and those receiving anticoagulation therapy or 
with a history of cardiovascular, rheumatic, and hematologic diseases were excluded. For 
this study, 150 patients with OA Kellgren grade 0 through IV were selected. Of those 
individuals, 50 were treated with PRP injections, 50 received low-molecular weight (LW 
HA) hyaluronic acid (molecular weight 500-730 kDa), and the rest were assigned high-
molecular weight (HW HA) hyaluronic acid (molecular weight 1000-2900 kDa) 
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injections.  Baseline characters were balanced among the single treatment group and two 
control groups. All participants received three injections administered every 14 days and 
outcomes were evaluated at 2 and 6 months post final injection. The primary outcomes of 
pain reduction and symptoms and function improvements were measured through the 
International Knee Document Committee (IKDC) and Visual Analogue Scale (EQ VAS) 
scoring system.11 
Injection preparation--PRP injections were prepared from 150ml autologous 
blood sample and centrifuged twice (1480rpm x 6min; 3400rpm x 15min) to separate red 
blood cells (RBC) and concentrate platelets. Kon et al11 states that this process resulted in 
a 6-fold increase in platelets when compared to whole blood. The remaining 20ml sample 
was divided equally into four tubes. One of the 5ml units was sent for laboratory analysis, 
two were stored at -30̊ C for future administration, and one was used immediately. 
Platelets were activated prior to injection using 10% calcium chloride.11  
Outcomes--Statistically significant improvements were noticed in all test groups 
with greater results in the PRP group. Evaluation of the IKDC score in the PRP group 
showed a steady increase from 41.2 (baseline) to 62.7 and 64.0 at 2 and 6 months follow 
up, respectively. Both HA groups initially increased their IKDC score by month 2, but 
this declined at the 6-month follow up. Baseline scores for LW HA were 44.7, then 61.7 
at 2 months and 53.8 at 6 months follow up. At baseline HW HA scores were 47.3, then 
54.8 and 54.0 at month 2 and 6, respectively. At the 2 months evaluation a major increase 
in IKDC scores was noted in the PRP and LW HA groups with lower scores in the HW 
HA group. However, by the 6-month follow up only the PRP group continued to show 
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higher scores. A separated, individual assessment of pain versus function alone was not 
discussed in this study in either treatment group or control groups. Further analysis 
showed that age was an issue in all three treatment groups with participants over the age 
of 50 demonstrating less improvements at 6 months follow up (P = 0.01). The degree of 
articular cartilage degeneration also seems to influence clinical outcome. Scores on the 
IKDC in the PRP group at 6-months follow up were higher in patients with mild OA 
(IKDC 74) when compared to individuals with severe OA (IKDC 46). In mild 
degeneration, PRP continued to increase from baseline to 6-month follow up (IKDC 41 to 
60), HW HA remained stable (IKDC 48 to 53), and LW HA initially showed an increase 
from baseline to 2 months ( IKDC 44 to 61) but this decreased at 6 months (IKDC 54). In 
advanced OA, PRP and LW HA decreased after a 2 months spike whereas HW HA 
stayed stable. Similar results were noted in the EQ VAS scoring system. No significant 
adverse reactions were reported during treatment and follow up. Plus, patient satisfaction 
in the PRP group was 82% compared to 64% in the LW HA and 66% in the HW HA.11 
(See Table 2)   
Spakova et al Trial 
Patient selection--The second study12 reviewed focused on the safety and 
efficacy of PRP injections in the treatment of knee OA. Patients included in this trial had 
a history of continuing knee pain for 12 months, imaging findings of OA Kellgren Grade 
1 through 3, and conservative therapy for the past 6 months without relief. Subjects with 
cofounding variables of thrombocytopenia, anemia, infections, systemic disease, and 
anticoagulation therapy were excluded. None of the patients enrolled received either 
glucocorticoid (GCS) or HA injections within 3 months of the beginning of the trial. This 
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prospective cohort study12 enrolled a total of 120 participants, who were randomly 
assigned into two equal groups of 60. Significant differences in baseline characters 
between these groups were not found. The treatment group received three PRP injections 
while the control group was treated with three 1.2% medium-molecular weight 
hyaluronic acid (MW HA) intra-articular visco-supplementations. Injections for both 
groups were administered once a week for three weeks. Follow up and evaluation 
occurred at 3 and 6 months post final treatment. Primary end points were measured using 
the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) and 11-
point pain intensity Numeric Rating Scale (NSR) with a focus on pain reduction and 
function improvements.12  
Injection preparation--A blood sample of 27ml venous blood was dispersed into 
“three 10ml tubes containing 1ml of 0.106M sodium citrate.”12 The anticoagulation agent 
was thoroughly mixed with the blood. An aliquot was removed for laboratory analysis. 
The remaining blood specimen underwent three centrifugations. After the first one 
(3200rpm x15min), RBC’s were separated and discarded. The second centrifugation 
(1500rpm x 10min) left a layer of white blood cells (WBC), which was disposed of. The 
third separation process (3200rpm x 10min) isolated the plasma into low and high levels 
of platelet concentration, with the low-levels being discarded.  A 4.5-fold increase in 
platelets was noted after the last centrifugation. The leftover of high platelet concentrated 
plasma was aspirated into a 3ml syringe and administered within 30minutes of 
preparation. Each injection was formulated at the time of visits and none of the PRP was 
activated with calcium chloride.12  
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Outcomes--The data analysis demonstrated a significantly better outcome in pain 
reduction and symptoms and function improvement in the PRP group when compared to 
the MW HA group. In the PRP group, the WOMAC scores initially decreased by 24.41 
points at 3 months but subsequently increased by 4.50 points from the 3-month to the 6-
month follow up. In addition, NRS scores were 5.27 at baseline, 2.06 at 3 months follow 
up, and 2.69 at the 6-month follow up, presenting a similar trend. In contrast, the MW 
HA control group displayed a WOMAC index decrease of 17.04 points at the 3-month 
evaluation and regained 4.73 points at 6 months follow up. Measurements on the NRS for 
the MW HA group also showed improvements, from 6.02 at baseline to 3.98 at 3-months 
follow up and to 4.3 at 6 month evaluation. Overall, both test groups demonstrated a 
noteworthy initial decrease in WOMAC and NRS scores during the first assessment at 3 
months. However, both scores seem to increase at the end of the 6-month follow up. The 
authors claim that the result of the comparison is encouraging and that PRP may be a 
good treatment option.  There were no other subgroup measurements such as difference 
in age and grade of OA, secondary outcome analysis, and separate evaluation of 
functional and symptoms improvement alone. No major complications were observed 
during this trial.12 (See Table 3)  
Sanchez et al Trial 
Patient selection--This observational retrospective cohort study13 was a 
preliminary attempt to gain insights into the effectiveness of PRP and its use for the 
treatment of knee OA. The authors of this study compared PRP therapy to HA intra-
articular injections in patients suffering from both idiopathic and also secondary 
traumatic and mechanical OA. Grading and assessment for eligibility were accomplished 
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through radiographic imaging and patients were diagnosed with OA using the American 
College of Rheumatology guidelines. The article does not state whether the researchers 
used the Kellgren grading criteria in classifying the level of OA in their test subjects. 
Patients with secondary OA due to autoimmune processes, generalized OA, arthroscopic 
intervention in the past year and intra-articular therapy in the past 3 months prior to the 
start of this trial were excluded. A total of 60 patients participated in this trial with 30 
individuals receiving PRP injections while the remaining participants were treated with 
2% HA intra-articular treatments. The authors did not specify whether the HA injection 
was of low, medium, or high molecular weight. A series of three injections were provided 
to all the patients at one-week intervals. Evaluation was conducted at 5 weeks post final 
treatment, using the WOMAC scoring system for assessment. Baseline characters were 
matched in both groups.13  
Injection preparation--A 34ml peripheral blood sample was obtained from the 
patient and dispensed into 9cc tubes containing 3.8% sodium citrate to prevent 
coagulation. The tubes were centrifuged only once at 640g for 8 minutes. The 2ml buffy 
coat and platelet concentrated plasma layer were retrieved and placed into an empty tube 
“under vertical air flow conditions.” Calcium chloride was added prior to administration 
to activate the platelets and a dosage of 6 to 8ml PRP was injected into the patient. No 
explanations regarding the varied doses were provided by the authors. This procedure 
yielded a moderate 2-fold increase in platelet concentration compared to peripheral 
blood.13  
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Outcomes--Primary outcomes were calculated “according to a reduction in 
WOMAC score of at least 40% from baseline”3 and was assessed by a blinded 
investigator. The article points out a potential financial bias, given the fact that three of 
the authors work for the company developing and selling PRP preparation kits. The 
study’s results reflected a significant improvement in joint pain, stiffness, and physical 
function in the PRP group after 5 weeks post final injection. The treatment group had a 
success rate of 33.3% in pain reduction. Baseline changes (P = 0.0043) in symptoms and 
function measurements were also noted in association to the PRP modality.  The control 
group presented with a 10% success rate regarding pain management and positive 
changes from baseline (P = 0.010) in symptoms and physical function were also 
observed. Assessment and evaluation of symptoms and function improvements 
individually were not addressed. Only a few mild adverse events were observed during 
treatment and follow up period.13  
DISCUSSION 
Successful treatments of articular cartilage degeneration and lesions have been 
difficult for most providers to achieve, and current therapeutic options have shown mixed 
results. The growing interests in the use of PRP in OA treatment, “which might provide 
cellular and humeral mediators to promote tissue healing and repair,”6 have gained 
momentum in the past few years and led to several studies.  Autologous plasma is a 
biological therapy approach with the goal of delivering concentrated platelets to 
accelerate and support the healing of injuries to hard and soft tissue without exposing the 
patient to major risks.7 Growth factors, an essential part of PRP, induce differentiation of 
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mesenchymal stem cells into chondrocytes and thereby increase cell proliferation. They 
also suppress inflammatory mediators such as interleukin-1, encourage matrix deposition, 
and slow down catabolism.8,14  Hence, growth factors help stabilize cartilage homeostasis 
and possibly reverse articular degeneration. The use of autologous blood versus synthetic 
chemicals also eliminates the risk for allergic reaction or disease transfer in addition to 
limiting possible drug toxicity.15 The simple and efficient in-house preparation at the time 
of patient visit proves to be of advantage for the PRP procedure. However, most 
insurance does not cover this treatment and the cost tends to be higher for PRP than for 
current therapy options.16 The use of venipuncture to obtain the blood should also be 
considered when prescribing PRP injections.  
All the studies reviewed, showed positive effects of PRP injections with 
improvements in symptoms and function in patients suffering from OA. Each trial 
demonstrated a noteworthy superiority of PRP injections when compared to HA visco-
supplementation at 2 to 6-month follow up. The overall results were promising without 
any major procedural complications. This was especially noticeable in the younger 
population and with less severe OA, as observed by Kon et al.11 The fact that older and 
more degenerative joints tend to have less viable cells and with that a smaller potential 
for growth factor response, might be the reason behind the low improvements in patients 
over the age of 50 and with severe OA. Yet despite lower results, patients with advanced 
OA still benefited from PRP. Kon et al11 speculates that additional biological 
mechanisms not currently known, are responsible for the improvement of OA symptoms.  
Considering the evidence, PRP injections with their ability for biological changes to the 
articular cartilage may be a worthwhile treatment option.   
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Nonetheless, it appears that each study prepared their PRP somewhat differently. 
Kon et al11 separated the blood sample twice at 1480rpm x 6 minutes and again at 
3400rpm x 15 minutes while Spakova et al12 used a stepwise approach of three 
centrifugations to concentrate the plasma (3200rpm x15min, 1500rpm x 10min, 3200rpm 
x 10min). Sanchez et al13, on the other hand, centrifuged the plasma only once at 640g x 
8 minutes. Though not clearly stated, it appears that Sanchez et al13 utilized an enzyme-
linked immunosorbent assay kit to quantify the amount of platelets and growth factors. In 
addition, Kon et al11 added calcium chloride prior to administration to activate the 
platelets. An anticoagulation agent was not used. Spakova et al12 did the reverse by 
adding sodium citrate to prevent coagulation but omitting the activation process. Sanchez 
et al13 opted, not only to add an anticoagulation agent, but also activate the platelets via 
calcium chloride. Furthermore, when measuring mean platelet concentration of PRP 
compared to whole blood, significant variations were noted amongst all three trials. 
While Kon et al11 mentioned a 600% increase in platelet concentration, Spakova et al12 
and Sanchez et al13 only observed a 450% and 200% rise, respectively. Each study 
administered a different dose to their test subject. Kon et al11 injected 5ml of PRP, 
whereas Spakova et al12 administered 3ml of the tested material and Sanchez et al13 used 
6 to 8ml of PRP in their injections. This leads to discussions as to whether the type of 
PRP preparation, injection dosage, number of platelets, and activation levels of 
administered PRP have an influence on the outcome. 
While the studies demonstrated significant pain reduction and improvement in 
physical function with PRP injections, they all had their limitations. Major flaws were 
noted in the Sanchez et al13 trial. Specific inclusion and exclusion criteria as well as 
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patient selection method were poorly defined. Kellgren grading system for radiological 
classifications of OA was not utilized. Follow-up data was not published, making 
comparison to baseline measurements and outcome success impossible to validate. 
Publication bias with conflict of interest was present as the main authors worked for the 
company selling PRP preparation systems commercially. Sample size of the Sanchez et 
al13 trial was too small for the study’s purpose.  Both, Sanchez et al13 and Spakova et al12, 
did not supply confidence intervals and p-values. There is also the possibility of over- or 
underestimation by the patient when answering the WOMAC, IKDC, EQ VAS, or NRS 
questionnaires in all trials, resulting in recall bias. In general, the strength of evidence 
would have been more substantial had all three studies used the same, most objective 
outcome measurement system. The WOMAC score assessed pain, stiffness, and function 
and decreases were observed as the symptoms improved. The IKDC scale measured pain 
and ADLs and scores increased as the patients felt better. In addition, each study used a 
different molecular weight HA for their control group, poorly defined the molecular 
weight component of the chosen HA visco-supplementation, and neither article disclosed  
the amount of HA administered to the test subjects. None of the trials discussed loss to 
follow up.  
To compare the pros and cons and determine the overall quality of evidence in all 
three studies, the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE)10 framework was used. Despite a “very low” grade for the Spakova 
et al13 trial due to several limitations, this systematic review received an overall “low” 
GRADE rating. Any further research done to expand on the use of PRP injection in the 
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treatment of OA is “very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate”10.  
Regardless of the “low” GRADE and limited data of the reviewed studies, it is 
reasonable and safe to recommend and allow patients who are curious about exploring 
biological and alternative therapy options for the treatment of knee OA to do so. Based 
on the encouraging evidence demonstrated by the three articles analyzed, practitioners 
should feel secure in recommending PRP injections to their patients suffering from OA, 
who otherwise have not found the relief for which they were looking. These patients may 
find PRP injections more acceptable and easier to tolerate than other interventions such 
as analgesics, steroid and non-steroid drugs, or physical therapy, allowing them to get the 
care and relief they desire. The use of HA is similarly acceptable but does have a 
different mechanism of action, therefore increasing the available choices.  
CONCLUSION 
The PRP procedure showed a higher degree of efficacy when compared to HA 
injections as well as significant findings of more and longer pain reduction, improved 
function, and patient satisfaction. This was particular noticeable in the treatment of 
younger patients with less severe articular cartilage degeneration. All of the studies 
suggest that PRP injections are a useful approach and alternative in the treatment of OA. 
This minimally invasive procedure appears to be safe and effective. It could be utilized as 
a reasonable treatment option should other therapies fail or are inappropriate for the 
particular patient.   
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However, the overall methodological quality of these three studies is considered 
to be low. More research is needed, with specific emphasis on blinded randomized 
control trials, to further confirm current positive findings and to determine the most 
effective platelet-concentration protocol, precise mechanism of action, its disease-
modifying properties, possible long-term effects, and its cost effectiveness. A suggestion 
made by Spakova et al12 is intriguing, as they discussed possible studies on PRP and HA 
combination treatments to determine a possible synergistic effect and to potentially 
produce greater symptomatic relief for patients with OA. These studies also should have 
a larger sample size to increase reliability and attempt to decide upon a standard method 
of measurement to enhance comparison.  
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TABLE 1 Characteristics of Reviewed Studies, 
GRADE profile 
 
 
 
ªSanchez et al does not provide post- treatment numbers to compare to outcome 
bTop three authors of Sanchez et al study showed conflict of interest as they worked for a company that commercially sells a system assisting with PRP preparations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality Assessment 
 Downgrade Criteria  Number of Patients   
No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely Study 
Treatment 
(total) 
Placebo or 
no treatment 
(total) 
Quality Importance 
Improve Symptoms and Function   
3 
 
2 prospective 
cohort 
1 retrospective 
cohort 
 No serious 
limitations 
No serious 
indirectness 
No serious 
imprecisionª 
No serious 
inconsistencies 
No bias 
likelyb 
Kon et al11 150 100 
Low Important Spakova et al12 120 60 
Sanchez et al13 60 30 
Patient Satisfaction   
1 
 
1 prospective 
cohort 
 
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely Kon et al
11 150 100 Low Important 
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TABLE 2 Outcome Scores for Kon et al11 
 
 
 
PRP LW HA HW HA 
IKDC 
Baseline 
2 months 
6 months 
41.2 ± 10.9 
62.7 ± 14.0 
64.0 ± 18.7 
44.7 ± 6.6 
61.7 ± 13.1 
53.8 ± 13.7 
47.3 ± 13.9 
54.8 ± 15.6 
54.0 ± 16.0 
EQ VAS 
Baseline 
2 months 
6 months 
53.6 ± 18.3 
73.0 ± 13.9 
72.3 ± 17.3 
51.2 ± 7.8 
68.7 ± 13.5 
61.7 ± 14.8 
52.2 ± 12.5 
63.0 ± 14.7 
62.4 ± 15.2 
IKDC = International knee document committee (Pain, function, ADL assessment); (0 = max. pain/Sx and loss of function, 100 = no pain/Sx and loss of function) 
EQ VAS = Visual analogue scale for pain assessment; (0 = max. pain, 100 = no pain) 
 
 
 
 
TABLE 3 Outcome Scores for Spakova et al12  
 
 
PRP HA 
WOMAC 
Baseline 
3 months 
6 months 
38.76 ± 16.50 
14.35 ± 14.18 
18.85 ± 14.09 
43.21 ± 13.70 
26.17 ± 17.47 
30.90 ± 16.57 
NRS 
Baseline 
3 months 
6 months 
5.27 ± 1.87 
2.06 ± 2.02 
2.69 ± 1.86 
6.02 ± 1.77 
3.98 ± 2.27 
4.3 ± 2.07 
WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index (Pain, function, ADL assessment); (0 = no pain/Sx and loss of function, 96 = max pain/Sx and 
loss of function) 
NRS = 11-point pain intensity Numeric Rating Scale (Pain assessment); (0 = no pain, 10 = max pain) 
 
 
 
